Löthgren M - Search Results

1

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E. Moeremans K, et al. Among authors: lothgren m. Pharmacoeconomics. 2010;28 Suppl 1:107-28. doi: 10.2165/11587480-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182347

2

Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Hill AM, Gebo K, Hemmett L, Löthgren M, Allegri G, Smets E. Hill AM, et al. Among authors: lothgren m. Pharmacoeconomics. 2010;28 Suppl 1:169-81. doi: 10.2165/11587510-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182350

3

Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.

Ghatnekar O, Hjortsberg C, Gisslén M, Lindbäck S, Löthgren M. Ghatnekar O, et al. Among authors: lothgren m. Pharmacoeconomics. 2010;28 Suppl 1:49-57. doi: 10.2165/11587440-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182343

4

Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Zethraeus N, Johannesson M, Jönsson B, Löthgren M, Tambour M. Zethraeus N, et al. Among authors: lothgren m. Pharmacoeconomics. 2003;21(1):39-48. doi: 10.2165/00019053-200321010-00003. Pharmacoeconomics. 2003. PMID: 12484802 Review.

5

Cost effectiveness of long-acting risperidone in Sweden.

Hensen M, Heeg B, Löthgren M, van Hout B. Hensen M, et al. Among authors: lothgren m. Appl Health Econ Health Policy. 2010;8(5):327-41. doi: 10.2165/11536180-000000000-00000. Appl Health Econ Health Policy. 2010. PMID: 20804225

6

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.

Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, van Hout B. Gandra SR, et al. Among authors: lothgren m. Clin Cardiol. 2016 Jun;39(6):313-20. doi: 10.1002/clc.22535. Epub 2016 Apr 19. Clin Cardiol. 2016. PMID: 27092712 Free PMC article.

7

Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.

Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A, Hout BV. Villa G, et al. Among authors: lothgren m. Clin Ther. 2017 Apr;39(4):771-786.e3. doi: 10.1016/j.clinthera.2017.02.011. Epub 2017 Mar 31. Clin Ther. 2017. PMID: 28366593

8

Definition, interpretation and calculation of cost-effectiveness acceptability curves.

Löthgren M, Zethraeus N. Löthgren M, et al. Health Econ. 2000 Oct;9(7):623-30. doi: 10.1002/1099-1050(200010)9:7<623::aid-hec539>3.0.co;2-v. Health Econ. 2000. PMID: 11103928

9

Do we fully understand the economic value of vaccines?

Drummond M, Chevat C, Lothgren M. Drummond M, et al. Among authors: lothgren m. Vaccine. 2007 Aug 10;25(32):5945-57. doi: 10.1016/j.vaccine.2007.04.070. Epub 2007 May 15. Vaccine. 2007. PMID: 17629362 Review.

10

Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.

Ghatnekar O, Alvegård T, Conradi N, Lenhoff S, Mellqvist UH, Persson U, Löthgren M. Ghatnekar O, et al. Among authors: lothgren m. Clin Ther. 2008 Sep;30(9):1704-13. doi: 10.1016/j.clinthera.2008.09.003. Clin Ther. 2008. PMID: 18840377

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page